BetterLife Pharma (BETRF) Non-Current Debt (2011 - 2026)

BetterLife Pharma has reported Non-Current Debt for 12 years, with the latest figure at $53418.8 in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 47.3% year-over-year to $53418.8 in Q2 2026; TTM through Apr 2026 was $53418.8, a 47.3% increase from a year earlier, with the FY2026 full-year figure at $53365.2, up 46.83% from the prior year.
• Non-Current Debt was $53418.8 for Q2 2026 at BetterLife Pharma, roughly flat from $53536.9 in the prior quarter.
• The five-year high for Non-Current Debt was $683037.4 in Q1 2022, with the low at $30115.8 in Q4 2022.
• Average Non-Current Debt over 5 years is $89326.0, with a median of $56268.2 recorded in 2026.
• The largest YoY upside for Non-Current Debt was 95.91% in 2023 against a maximum downside of 91.32% in 2023.
• Over 5 years, Non-Current Debt stood at $30115.8 in 2022, then jumped by 95.91% to $58999.5 in 2023, then climbed by 16.84% to $68932.5 in 2024, then sank by 42.94% to $39330.2 in 2025, then jumped by 35.82% to $53418.8 in 2026.
• The last three Non-Current Debt figures came in at $53418.8 (Q2 2026), $53536.9 (Q1 2026), and $39330.2 (Q3 2025), per Business Quant data.